​

ADC Therapeutics (ADCT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ADCT Stock Forecast

ADC Therapeutics (ADCT) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $9.33, with a high of $13.00 and a low of $7.00. This represents a 671.07% increase from the last price of $1.21.

- $3 $6 $9 $12 $15 High: $13 Avg: $9.33 Low: $7 Last Closed Price: $1.21

ADCT Stock Rating

ADC Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (70.00%), 3 Hold (30.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 3 7 Strong Sell Sell Hold Buy Strong Buy

ADCT Price Target Upside V Benchmarks

TypeNameUpside
StockADC Therapeutics671.07%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$8.00
Last Closing Price$1.21$1.21$1.21
Upside/Downside--561.16%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2524---6
Mar, 25241--7
Feb, 25241--7
Jan, 25241--7
Dec, 24241--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 07, 2024Robert BurnsH.C. Wainwright$8.00$4.4579.78%561.16%
Mar 13, 2024Kelly ShiJefferies$13.00$3.90233.33%974.38%
Nov 14, 2022Morgan Stanley$7.00$4.1070.73%478.51%
Sep 09, 2022Matthew HarrisonMorgan Stanley$11.00$6.5268.71%809.09%
Aug 22, 2022H.C. Wainwright$20.00$8.42137.53%1552.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 30, 2024Cantor FitzgeraldOverweightinitialise
May 07, 2024H.C. WainwrightBuyBuyhold
Feb 20, 2024NeedhamBuyBuyhold
Aug 10, 2023Deutsche BankHolddowngrade
Nov 14, 2022Morgan StanleyEqual-WeightEqual-Weighthold
Sep 19, 2022H.C. WainwrightBuyBuyhold
May 10, 2022RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.77$-3.00$-1.99$-2.94$-1.62----
Avg Forecast$-3.53$-3.44$-2.07$-2.39$-1.71$-1.54$-1.18$-0.90$-0.33
High Forecast$-3.34$-3.26$-1.98$-2.14$-1.42$-1.19$-0.86$-0.67$-0.31
Low Forecast$-3.91$-3.82$-2.18$-2.54$-1.89$-1.82$-1.70$-1.32$-0.35
Surprise %6.80%-12.79%-3.86%23.01%-5.26%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$33.92M$209.91M$69.56M$69.28M----
Avg Forecast$1.29M$33.01M$187.67M$68.07M$72.72M$81.02M$113.22M$177.00M$268.70M
High Forecast$1.39M$35.78M$195.08M$68.37M$73.03M$83.54M$113.22M$181.68M$282.60M
Low Forecast$1.23M$31.66M$181.53M$67.64M$72.41M$78.98M$113.22M$172.32M$257.73M
Surprise %-2.75%11.85%2.18%-4.72%----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-246.29M$-230.03M$-155.80M$-240.05M$-157.85M----
Avg Forecast$-288.28M$-281.21M$-169.14M$-191.38M$-135.25M$-122.75M$-104.59M$-81.30M$-27.13M
High Forecast$-272.99M$-266.29M$-161.95M$-175.15M$-116.29M$-96.84M$-70.27M$-54.75M$-25.69M
Low Forecast$-319.73M$-311.88M$-177.82M$-207.62M$-154.22M$-148.66M$-138.91M$-107.86M$-28.95M
Surprise %-14.57%-18.20%-7.89%25.43%16.70%----

ADCT Forecast FAQ

Is ADC Therapeutics stock a buy?

ADC Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ADC Therapeutics is a favorable investment for most analysts.

What is ADC Therapeutics's price target?

ADC Therapeutics's price target, set by 10 Wall Street analysts, averages $9.33 over the next 12 months. The price target range spans from $7 at the low end to $13 at the high end, suggesting a potential 671.07% change from the previous closing price of $1.21.

How does ADC Therapeutics stock forecast compare to its benchmarks?

ADC Therapeutics's stock forecast shows a 671.07% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for ADC Therapeutics over the past three months?

  • April 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is ADC Therapeutics’s EPS forecast?

ADC Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.54, marking a -4.94% decrease from the reported $-1.62 in 2024. Estimates for the following years are $-1.18 in 2026, $-0.9 in 2027, and $-0.33 in 2028.

What is ADC Therapeutics’s revenue forecast?

ADC Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $81.02M, reflecting a 16.95% increase from the reported $69.28M in 2024. The forecast for 2026 is $113.22M, followed by $177M for 2027, and $268.7M for 2028.

What is ADC Therapeutics’s net income forecast?

ADC Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-123M, representing a -22.24% decrease from the reported $-158M in 2024. Projections indicate $-105M in 2026, $-81.304M in 2027, and $-27.128M in 2028.